Bill began his industrial career as a venture associate at Paramount Capital. He then worked in medical affairs at Roche Laboratories. In '99, he co-founded and was CEO of BioBid, a venture-backed company. In '00, Bill founded an independent strategic advisory practice, which was incorporated as EGB Advisors, LLC in '02. He performed his residency in anatomic pathology at Columbia-Presbyterian and earned a Master of Public Health at Harvard.

Investment Banking
EGB actively represents both public and private companies. We look for revenue generating companies and portfolios. In addition to working as investment bankers, we co-invest with our clients.

Technology Commercialization
EGB licenses high-value university technologies, making seed investments. We are interested in learning about projects with clinical data. Earlier-stage projects with a very compelling pre-clinical package suggesting a novel indication for a marketed compound are also of interest.

Anne De Gheest founded MedStars in 1986 and specializes in Medical Devices, Services and Healthcare Information Systems. She has held leadership positions in starting or building new Life Science companies with a cumulative market cap today over $4 Billion. She held operating executive positions at Raychem and in the founding teams of Nellcor, OmniCell and MedPool. She had key roles as acting executive or hands-on advisor in the early days of Pyxis, Aspect Medical, VISX, ProDuct and Thermage. She was an entrepreneur in residence with IVP and has a Master's in Commercial Engineering from the University of Brussels and an MBA from Harvard.

MedStars, an investment and executive management firm, has specialized over the last 17 years in starting and developing new life sciences companies with innovative products and services. By providing access to seed capital and operational hands-on expertise, MedStars brings to early stage healthcare companies the financial and business expertise needed to get the companies off the ground. MedStars then helps these companies to prove technical and market feasibility, develop sound business models and attract permanent senior management in order to be financed by venture firms or corporate partners

Evgeny joined Asset Management in 2001 as an Associate.

He was previously Chief Scientific and Executive Officer at the Medico-Ecological Institute in Barnaul, Siberia, Russia, which was responsible for studying the health and environmental effects of the Soviet Union's nuclear testing program. The Institute developed into an internationally recognized research center during his seven years' tenure.

Evgeny received his MD with honors and PhD from Altai Medical University in Barnaul, Russia, and his MBA from the Stanford University Graduate School of Business. At Asset Management, Evgeny focuses on early-stage investments in biotechnology and medical device companies. He is a member of the Board of Directors of Asilomar Pharmaceuticals, Inc.